核苷酸抗病毒治疗慢性乙肝对肾功能的影响探讨

发布时间：2018-05-24 03:24

本文选题：核苷酸抗病毒 + 肾功能　；参考：《现代诊断与治疗》2016年24期

【摘要】：选取我院收治的慢性乙肝患者,其中拒绝使用核苷酸抗病毒药物的作为阴性对照组,其余按给药不同分拉米夫定(LAM)组、阿德福韦酯(ADV组)、替比夫定(LDT)组和恩替卡韦(ETV)组。比较各组患者的估算肾小球率过滤(e GFR)、血肌酐(Cr)和尿素氮(BUN)。LAM组、ETV组队患者e GFR无明显影响,而ADV组可降低患者e GFR,相反LDT可升高患者的e GFR,改善肾功,差异有统计学意义(P0.05)。ADV组可升高患者Cr水平(P0.05),而对BUN水平无明显影响,其余各组对Cr和BUN均无明显影响。替比夫定可改善慢性乙型肝炎患者e GFR水平,改善肾功能,而阿德福韦酷降低e GFR,升高血肌酐水平,造成肾功能损伤。
[Abstract]:The patients with chronic hepatitis B in our hospital were selected as negative control group. The others were divided into lamivudine group, adefovir group, tibivudine group and entecavir group according to the administration of Lamivudine (Lam), tibivudine (LDT) and entecavir (ETV). Comparing the estimated glomerular rate of each group with serum creatinine (Cr) and bun BUN.LAM group, there was no significant effect on e GFR in ETV group, while ADV group could decrease the eGFR.On the contrary, LDT could increase the level of eGFR and improve renal function. The difference was statistically significant (P 0.05). ADV could increase the level of Cr and P0.05, but had no significant effect on the level of BUN, while the other groups had no significant effect on Cr and BUN. Tibivudine can improve the level of e GFR and renal function in patients with chronic hepatitis B, while adefovir can decrease the level of e GFR, increase the level of creatinine, and cause renal function damage.
【作者单位】：东莞东华医院感染科;
【分类号】：R512.62

【参考文献】